Hutchmed (China) Limited

Description

Founded in 2000, Hutchmed (China) Limited, formerly Hutchison China Meditech Ltd, is an innovative, commercial stage biopharmaceutical company, engaged in discovery and development of targeted therapies and immunotherapies for the treatment of immunological diseases and cancer. It is the first global-focused novel drug discovery companies in China with pipeline of 12 clinical stage drug candidates in clinical studies across the world, 11 of which were discovered by its in-house scientific team and have three oncology drugs approved and marketed in china.  The company has also developed a profitable commercial platform that produces markets and distributes its novel oncology products, consumer health products and prescription drugs in China. The company is listed on the London Stock exchange as LON: HCM and on the Nasdaq Global Select Market as LON: HKEX.

The company has brought three of its internally developed drugs to patients that are in lat stage of development. The company offers a range of products such as ELUNATE (fruquintinib), SULANDA (Surufatinib) and ORPATHYS (Savolitinib).     ELUNATE (fruquintinib) is an oral inhibitor of vascular endothelial growth factor receptor (VEGFR) 1/2/3 that plays a pivotal role in blocking tumor angiogenesis and is approved in China but not outside. SULANDA (Surufatinib) is a novel, oral angio-immuno kinase inhibitor that inhibits the tyrosine kinase activity associated with fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR), that inhibit angiogenesis and colony stimulating factor-1 receptor (CSF-1R).

It is approved in China but not outside. ORPATHYS (Savolitinib) is an oral selective MEF THI that clocks atypical activation of the MET receptor tyrosine kinase pathway. It is also approved in China but not outside. The company’s drug pipeline includes MET, FGFR, CSF-1R, VEGFR, PI3Kδ, IDH, ERK, Syk, BTK, EGFR and CD47 and some are being investigated both as potential single agents and in combinations.